Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JANUS: FOLFIRINOX vs FOLFOX/CAPOX in Locally Advanced Rectal Cancer
NCT05610163Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2022
- Primary completion
- Jul 2030
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer, sponsored by Cancer and Leukemia Group B. Started Dec 2022; status: active, not recruiting.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05610163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610163.